Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cancer patients to be available throughout China Oxford UK, and Shanghai China March 7th 2018 The launch of ColoProg represents a first for precision oncology in Greater…
Oxford, UK, 9th October 2017 Oxford Cancer Biomarkers has appointed healthcare industry leader David Browning as Chief Executive Officer and member of the Board. This represents an important milestone for the company which aims to benefit cancer patients through the…
Oxford, UK, 1st September 2017 The announcement, at the 3rd China Medical Devices Int’l Summit, follows the signing in March 2017 of a memorandum of strategic collaboration between Oxford Cancer Biomarkers (OCB) and Ningbo My-BioMed Biotechnology Co. Ltd (MBM). MBM…
Investment will drive rapid uptake of OCB’s cancer tests and expand its development pipeline Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced…
Collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People’s Republic of China Oxford, UK, April 2017 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to…
Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering chemotherapy Oxford, UK, 14th March 2017 – FOR IMMEDIATE RELEASE Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow personalised medicine for cancer patients,…
First patient enrolled in clinical utility study Oxford, UK, 9th November 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the…
Oxford, UK, 10 June 2016 Oxford Cancer Biomarkers has appointed Kathryn Kuhne as Commercial and Marketing Director, a key growth milestone for the company which aims to benefit cancer patients through developing molecular diagnostic tests that allow improved treatment decisions.…
Oxford, UK, 18 January 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a partnership with Room4 a UK based imaging company…
Oxford, UK, 14 December 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that it has secured new investment. Longwall Ventures co-invested…